Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (148,208) | (19,948) |
| Maturities of available-for-sale debt securities | 25,059 | 35,472 |
| Purchases of property and equipment | (135) | (16) |
| Net cash (used in) provided by investing activities | (123,284) | 15,508 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs of $29.6 million | 317,165 | - |
| Principal payments on finance lease | (46) | (59) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s capex?
- Hemab Therapeutics Holdings, Inc. (COAG) reported capex of $23K in Q2 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude